Antigen epitope peptide combination of a broad-spectrum novel coronavirus vaccine and application thereof

By designing a combination of Epi-I, Epi-II, and Epi-III antigenic epitope peptides of the viral spike protein, the problem of existing vaccines being unable to cope with multiple viral variants was solved, and the broad-spectrum neutralizing antibody response and cross-neutralization effects were improved.

CN121135894BActive Publication Date: 2026-05-26INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Filing Date
2025-10-13
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Existing novel coronavirus vaccines are unable to effectively induce a broad-spectrum neutralizing antibody response and cannot effectively combat multiple viral variants, resulting in weakened immune protection and an increased risk of immune escape.

Method used

Design a broad-spectrum novel coronavirus vaccine antigenic epitope peptide combination, including a combination of viral spike protein Epi-I, Epi-II and Epi-III antigenic epitope peptides, and induce a broad-spectrum neutralizing antibody response by linking them through amino acids or peptides to prepare a broad-spectrum novel coronavirus vaccine.

Benefits of technology

It achieved broad-spectrum neutralizing protection against multiple novel coronavirus variants, enhanced the immunoprotective efficacy of the vaccine, and significantly improved the cross-neutralization effect against variants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121135894B_ABST
    Figure CN121135894B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology, specifically relating to an antigenic epitope peptide combination for a broad-spectrum novel coronavirus vaccine and its application. The antigenic epitope peptide combination of this invention includes a combination of viral spike protein Epi-I antigenic epitope peptides, a combination of viral spike protein Epi-II antigenic epitope peptides, and a combination of viral spike protein Epi-III antigenic epitope peptides. These antigenic epitope peptide combinations are obtained by screening spike protein epitopes from three broad-spectrum neutralizing antibodies against SARS-CoV-2, and can induce a broad-spectrum neutralizing antibody response in the host, used for the preparation of a broad-spectrum novel coronavirus vaccine. Using the antigenic epitope peptide combination of this invention, an antigenic epitope fusion protein L9 was obtained and prepared into a vaccine. The results of the examples show that the L9 vaccine has a better neutralizing effect against SARS-CoV-2 variants than the control group of the Wuhan strain of SARS-CoV-2 spike protein RBD, exhibiting good cross-neutralization.
Need to check novelty before this filing date? Find Prior Art